{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T18:09:58Z","timestamp":1781719798515,"version":"3.54.5"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"45","license":[{"start":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T00:00:00Z","timestamp":1759536000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T00:00:00Z","timestamp":1759536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA269211"],"award-info":[{"award-number":["R01 CA269211"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2025,11,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Lipid metabolism is among the most frequently dysregulated metabolic processes in human cancer, yet how cellular lipids, the end products of lipogenesis, and their composition are altered to support various aspects of cancer remains poorly understood. Here, we show that targeting SREBP-dependent lipogenesis via FGH10019, an orally available SREBP inhibitor, enhances docetaxel-induced cytotoxicity in human prostate cancer cells in vitro and in vivo. Mechanistically, suppression of lipid biosynthesis leads to a shift in cellular lipid composition toward polyunsaturated lipids, resulting in increased membrane permeability and intracellular docetaxel accumulation. Thus, our findings reveal a critical role of de novo lipogenesis in protecting cancer cells from chemotherapeutics and suggest that treatment with lipogenesis inhibitors could improve the efficacy of chemotherapy against human prostate cancer.<\/jats:p>","DOI":"10.1038\/s41388-025-03588-6","type":"journal-article","created":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T19:26:37Z","timestamp":1759605997000},"page":"4405-4412","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeting SREBP-dependent lipogenesis potentiates the anti-tumor activity of docetaxel by increasing membrane permeability and intracellular drug accumulation"],"prefix":"10.1038","volume":"44","author":[{"given":"Jiaqi","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5953-3499","authenticated-orcid":false,"given":"Mu-En","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa R.","family":"Bawcom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Asara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4928-8722","authenticated-orcid":false,"given":"Lei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3470-1062","authenticated-orcid":false,"given":"Ming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,4]]},"reference":[{"key":"3588_CR1","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502\u201312.","journal-title":"N Engl J Med"},{"key":"3588_CR2","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1091\/mbc.10.4.947","volume":"10","author":"AM Yvon","year":"1999","unstructured":"Yvon AM, Wadsworth P, Jordan MA. Taxol suppresses dynamics of individual microtubules in living human tumor cells. Mol Biol Cell. 1999;10:947\u201359.","journal-title":"Mol Biol Cell"},{"key":"3588_CR3","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.euf.2016.10.006","volume":"2","author":"N Mottet","year":"2016","unstructured":"Mottet N. Metastatic castration-resistant prostate cancer: major progress leading to even more questions. Eur Urol Focus. 2016;2:562\u20134.","journal-title":"Eur Urol Focus"},{"key":"3588_CR4","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1056\/NEJMra1701695","volume":"378","author":"O Sartor","year":"2018","unstructured":"Sartor O, de Bono JS. Metastatic prostate cancer. N Engl J Med. 2018;378:645\u201357.","journal-title":"N Engl J Med"},{"key":"3588_CR5","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646\u201374.","journal-title":"Cell"},{"key":"3588_CR6","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1093\/pcmedi\/pbz017","volume":"2","author":"M Chen","year":"2019","unstructured":"Chen M, Huang J. The expanded role of fatty acid metabolism in cancer: new aspects and targets. Precis Clin Med. 2019;2:183\u201391.","journal-title":"Precis Clin Med"},{"key":"3588_CR7","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1515\/bchm3.1986.367.2.905","volume":"367","author":"L Weiss","year":"1986","unstructured":"Weiss L, Hoffmann GE, Schreiber R, Andres H, Fuchs E, K\u00f6rber E, et al. Fatty-acid biosynthesis in man, a pathway of minor importance. Purification, optim assay cond, organ distrib fat-acid synthase. Biol Chem Hoppe Seyler. 1986;367:905\u201312.","journal-title":"Biol Chem Hoppe Seyler"},{"key":"3588_CR8","first-page":"793","volume":"27","author":"JR Sabine","year":"1967","unstructured":"Sabine JR, Abraham S, Chaikoff IL. Control of lipid metabolism in hepatomas: insensitivity of rate of fatty acid and cholesterol synthesis by mouse hepatoma BW7756 to fasting and to feedback control. Cancer Res. 1967;27:793\u20139.","journal-title":"Cancer Res"},{"key":"3588_CR9","first-page":"R146","volume":"247","author":"M Ookhtens","year":"1984","unstructured":"Ookhtens M, Kannan R, Lyon I, Baker N. Liver and adipose tissue contributions to newly formed fatty acids in an ascites tumor. Am J Physiol. 1984;247:R146\u2013153.","journal-title":"Am J Physiol"},{"key":"3588_CR10","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s41588-017-0027-2","volume":"50","author":"M Chen","year":"2018","unstructured":"Chen M, Zhang J, Sampieri K, Clohessy JG, Mendez L, Gonzalez-Billalabeitia E, et al. An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer. Nat Genet. 2018;50:206\u201318.","journal-title":"Nat Genet"},{"key":"3588_CR11","doi-asserted-by":"publisher","first-page":"4923","DOI":"10.1021\/jm200304y","volume":"54","author":"S Kamisuki","year":"2011","unstructured":"Kamisuki S, Shirakawa T, Kugimiya A, Abu-Elheiga L, Choo HY, Yamada K, et al. Synthesis and evaluation of diarylthiazole derivatives that inhibit activation of sterol regulatory element-binding proteins. J Med Chem. 2011;54:4923\u20137.","journal-title":"J Med Chem"},{"key":"3588_CR12","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/sj.bjc.6601581","volume":"90","author":"RJ Veldman","year":"2004","unstructured":"Veldman RJ, Zerp S, van Blitterswijk WJ, Verheij M. N-hexanoyl-sphingomyelin potentiates in vitro doxorubicin cytotoxicity by enhancing its cellular influx. Br J Cancer. 2004;90:917\u201325.","journal-title":"Br J Cancer"},{"key":"3588_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/srep01949","volume":"3","author":"AJ van Hell","year":"2013","unstructured":"van Hell AJ, Melo MN, van Blitterswijk WJ, Gueth DM, Braumuller TM, Pedrosa LR, et al. Defined lipid analogues induce transient channels to facilitate drug-membrane traversal and circumvent cancer therapy resistance. Sci Rep. 2013;3:1949.","journal-title":"Sci Rep."},{"key":"3588_CR14","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/jps.2600760108","volume":"76","author":"GM Golden","year":"1987","unstructured":"Golden GM, McKie JE, Potts RO. Role of stratum corneum lipid fluidity in transdermal drug flux. J Pharm Sci. 1987;76:25\u201328.","journal-title":"J Pharm Sci"},{"key":"3588_CR15","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ctrv.2016.10.008","volume":"52","author":"S Zalba","year":"2017","unstructured":"Zalba S, Ten Hagen TL. Cell membrane modulation as adjuvant in cancer therapy. Cancer Treat Rev. 2017;52:48\u201357.","journal-title":"Cancer Treat Rev"},{"key":"3588_CR16","doi-asserted-by":"crossref","unstructured":"Wang ME, Chen J, Lu Y, Bawcom AR, Wu J, Ou J, et al. RB1-deficient prostate tumor growth and metastasis are vulnerable to ferroptosis induction via the E2F\/ACSL4 axis. J Clin Investig. 2023;133:e166647.","DOI":"10.1172\/JCI166647"},{"key":"3588_CR17","doi-asserted-by":"crossref","unstructured":"Loh ZN, Wang ME, Wan C, Asara JM, Ji Z, Chen M. Nuclear PTEN regulates thymidylate biosynthesis in human prostate cancer cell lines. Metabolites. 2023;13:939.","DOI":"10.3390\/metabo13080939"},{"key":"3588_CR18","doi-asserted-by":"publisher","first-page":"8117","DOI":"10.1158\/0008-5472.CAN-09-3871","volume":"70","author":"E Rysman","year":"2010","unstructured":"Rysman E, Brusselmans K, Scheys K, Timmermans L, Derua R, Munck S, et al. De novo lipogenesis protects cancer cells from free radicals and chemotherapeutics by promoting membrane lipid saturation. Cancer Res. 2010;70:8117\u201326.","journal-title":"Cancer Res"},{"key":"3588_CR19","first-page":"3864","volume":"19","author":"C Yang","year":"2019","unstructured":"Yang C, Zhang W, Wang J, Chen P, Jin J. Effect of docetaxel on the regulation of proliferation and apoptosis of human prostate cancer cells. Mol Med Rep.2019;19:3864\u201370.","journal-title":"Mol Med Rep."},{"key":"3588_CR20","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1530\/ERC-18-0284","volume":"26","author":"W Guan","year":"2019","unstructured":"Guan W, Hu J, Yang L, Tan P, Tang Z, West BL, et al. Inhibition of TAMs improves the response to docetaxel in castration-resistant prostate cancer. Endocr Relat Cancer. 2019;26:131\u201340.","journal-title":"Endocr Relat Cancer"},{"key":"3588_CR21","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.ccr.2012.07.016","volume":"22","author":"J Domingo-Domenech","year":"2012","unstructured":"Domingo-Domenech J, Vidal SJ, Rodriguez-Bravo V, Castillo-Martin M, Quinn SA, Rodriguez-Barrueco R, et al. Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells. Cancer Cell. 2012;22:373\u201388.","journal-title":"Cancer Cell"},{"key":"3588_CR22","doi-asserted-by":"publisher","first-page":"12027","DOI":"10.1073\/pnas.1534923100","volume":"100","author":"JD Horton","year":"2003","unstructured":"Horton JD, Shah NA, Warrington JA, Anderson NN, Park SW, Brown MS, et al. Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proc Natl Acad Sci USA. 2003;100:12027\u201332.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3588_CR23","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s10555-024-10170-1","volume":"43","author":"R Vishwa","year":"2024","unstructured":"Vishwa R, BharathwajChetty B, Girisa S, Aswani BS, Alqahtani MS, Abbas M, et al. Lipid metabolism and its implications in tumor cell plasticity and drug resistance: what we learned thus far? Cancer Metastasis Rev. 2024;43:293\u2013319.","journal-title":"Cancer Metastasis Rev"},{"key":"3588_CR24","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jconrel.2014.05.012","volume":"190","author":"C Bourgaux","year":"2014","unstructured":"Bourgaux C, Couvreur P. Interactions of anticancer drugs with biomembranes: what can we learn from model membranes? J Control Release. 2014;190:127\u201338.","journal-title":"J Control Release"},{"key":"3588_CR25","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.tem.2008.11.002","volume":"20","author":"JL Watts","year":"2009","unstructured":"Watts JL. Fat synthesis and adiposity regulation in Caenorhabditis elegans. Trends Endocrinol Metab. 2009;20:58\u201365.","journal-title":"Trends Endocrinol Metab"},{"key":"3588_CR26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/2049-3002-1-3","volume":"1","author":"B Griffiths","year":"2013","unstructured":"Griffiths B, Lewis CA, Bensaad K, Ros S, Zhang Q, Ferber EC, et al. Sterol regulatory element binding protein-dependent regulation of lipid synthesis supports cell survival and tumor growth. Cancer Metab. 2013;1:3.","journal-title":"Cancer Metab"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03588-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03588-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03588-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T23:02:52Z","timestamp":1762210972000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03588-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,4]]},"references-count":26,"journal-issue":{"issue":"45","published-print":{"date-parts":[[2025,11,25]]}},"alternative-id":["3588"],"URL":"https:\/\/doi.org\/10.1038\/s41388-025-03588-6","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,4]]},"assertion":[{"value":"22 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. All animal procedures were approved by the Duke Institutional Animal Care and Use Committee under protocol A195-21-09. No human subjects were involved in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}